Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T13:46:12.237Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T13:46:12.237Z.
Quote observation: 2026-10-06T13:44:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
FORWARD PE RATIO
N/A
Conexeu Sciences Inc.
Market Cap
$87.50M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Conexeu Sciences Inc. (CNXU) | $87.50M | N/A |
| CareCloud, Inc. (CCLD)vs › | $87.54M | 7.49 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $87.10M | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $88.63M | N/A |
| ImmuCell Corporation (ICCC)vs › | $89.11M | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.83M | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $85.52M | 9.20 |
| Equillium, Inc. (EQ)vs › | $89.78M | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.76M | N/A |
| electroCore, Inc. (ECOR)vs › | $91.96M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
